The leadership of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) held a series of high-level meetings with senior government officials recently to chart strategic priorities, align policies, and explore growth opportunities for India’s pharmaceutical exports.
The PHARMEXCIL delegation included Namit Joshi, Chairman; Nipun Jain, Chairman – iPHEX 2026 & MSME Committee; and Raja Bhanu, Director General.
During a meeting with Rajesh Agrawal, Secretary, Department of Commerce and Industry, the delegation highlighted India’s pharmaceutical export performance, which reached USD 30.47 billion in FY 2024–25, registering 9.4 percent year-on-year growth. The delegation expressed optimism that exports are on track to surpass last year’s performance.
PHARMEXCIL also noted it ranks 4th among all Export Promotion Councils (EPCs) in export performance, underscoring the sector’s vital role in India’s overall trade. The Council praised the Department’s support for flagship initiatives such as the Chintan Shivir programme, a series of regional conferences for engaging pharmaceutical MSMEs, with upcoming editions planned in Ahmedabad and Hyderabad. The delegation also briefed the Secretary on iPHEX 2026, scheduled for September 7–9, 2026, at Bharat Mandapam, New Delhi.
In a separate meeting with Manoj Joshi, Secretary, Department of Pharmaceuticals, PHARMEXCIL emphasized the sector’s strong growth trajectory. While exports have reached US$ 30.47 billion, India’s domestic pharmaceutical market—currently valued at US$ 60 billion—is projected to reach US$ 130 billion by 2030.
Discussions with the Department of Pharmaceuticals focused on advancing industry–academia collaboration to fuel innovation, skills, and future-ready pharma capabilities
The delegation highlighted India’s standing as the third-largest pharmaceutical producer globally by volume, supplying affordable, quality-assured medicines to over 150 countries.
Discussions with Satya Prakash L, Joint Secretary, Department of Pharmaceuticals, focused on strengthening industry–academia collaboration across clinical trials, biopharmaceuticals, vaccines, and APIs, with emphasis on innovation, skill development, and capacity building.
The delegation also met Lav Aggarwal, Director General, DGFT, to brief him on PHARMEXCIL’s key initiatives and seek continued support for Chintan Shivir and iPHEX 2026.
Commenting on the engagements, Namit Joshi, Chairman, PHARMEXCIL, said, "India’s pharmaceutical sector stands at a pivotal inflection point. With strong export momentum, a rapidly expanding domestic market, and consistent government support, we are well-positioned to scale our global footprint while reinforcing India’s reputation as a trusted pharmacy of the world.”
Nipun Jain, Chairman – iPHEX 2026 & MSME Committee, PHARMEXCIL added, “Platforms like Chintan Shivir and iPHEX are critical enablers for MSMEs and exporters. They not only facilitate market access but also foster dialogue around quality, innovation, and global competitiveness.”
